BIOLOGICAL
HM15211 or Placebo
Long-acting tri-agonist
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Status
Completed
Phase
Phase 1
Enrollment
41
Locations
1
Results
Posted
Publications
0
Study summary
What the protocol is testing.
Single ascending dose of HM15211 in healthy obese subjects.
Full detailed description
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Dec 15, 2017
Study start
Apr 4, 2018
Primary completion
Sep 14, 2018
Study completion
Sep 14, 2018
Results posted
May 17, 2024
Registry updated
Feb 6, 2025
Outcomes
What the study measures.
Primary outcomes
Number of Participants With Adverse Events
Time frame · 1 month
An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Female subjects must be non-pregnant and non-lactating Exclusion Criteria: * Participation in an investigational study within 30 days prior to dosing
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Hanmi Investigative Site
Chula Vista, California, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Efocipegtrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis
Phase 2
Active, not recruiting
215
2026-06
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
Hanmi Pharmaceutical Company Limited · NAFLD
Phase 1
Completed
66
2025-01
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.